Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Corrigendum to Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity.

Bal-Price A, Hogberg HT, Crofton KM, Daneshian M, FitzGerald RE, Fritsche E, Heinonen T, Hougaard Bennekou S, Klima S, Piersma AH, Sachana M, Shafer TJ, Terron A, Monnet-Tschudi F, Viviani B, Waldmann T, Westerink RHS, Wilks MF, Witters H, Zurich MG, Leist M.

ALTEX. 2019;36(3):506. doi: 10.14573/altex.1904112.

PMID:
31329255
2.

Protein pathway analysis to study development-dependent effects of acute and repeated trimethyltin (TMT) treatments in 3D rat brain cell cultures.

Schvartz D, González-Ruiz V, Walter N, Antinori P, Jeanneret F, Tonoli D, Boccard J, Zurich MG, Rudaz S, Monnet-Tschudi F, Sandström J, Sanchez JC.

Toxicol In Vitro. 2019 Jun 7;60:281-292. doi: 10.1016/j.tiv.2019.05.020. [Epub ahead of print]

PMID:
31176792
3.

An Integrative Multi-Omics Workflow to Address Multifactorial Toxicology Experiments.

González-Ruiz V, Schvartz D, Sandström J, Pezzatti J, Jeanneret F, Tonoli D, Boccard J, Monnet-Tschudi F, Sanchez JC, Rudaz S.

Metabolites. 2019 Apr 24;9(4). pii: E79. doi: 10.3390/metabo9040079.

4.

In vitro models to study insulin and glucocorticoids modulation of trimethyltin (TMT)-induced neuroinflammation and neurodegeneration, and in vivo validation in db/db mice.

Sandström J, Kratschmar DV, Broyer A, Poirot O, Marbet P, Chantong B, Zufferey F, Dos Santos T, Boccard J, Chrast R, Odermatt A, Monnet-Tschudi F.

Arch Toxicol. 2019 Jun;93(6):1649-1664. doi: 10.1007/s00204-019-02455-0. Epub 2019 Apr 16.

PMID:
30993381
5.

Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity.

Bal-Price A, Hogberg HT, Crofton KM, Daneshian M, FitzGerald RE, Fritsche E, Heinonen T, Hougaard Bennekou S, Klima S, Piersma AH, Sachana M, Shafer TJ, Terron A, Monnet-Tschudi F, Viviani B, Waldmann T, Westerink RHS, Wilks MF, Witters H, Zurich MG, Leist M.

ALTEX. 2018;35(3):306-352. doi: 10.14573/altex.1712081. Epub 2018 Feb 23. Erratum in: ALTEX. 2019;36(3):506.

6.

Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes.

Fritsche E, Grandjean P, Crofton KM, Aschner M, Goldberg A, Heinonen T, Hessel EVS, Hogberg HT, Bennekou SH, Lein PJ, Leist M, Mundy WR, Paparella M, Piersma AH, Sachana M, Schmuck G, Solecki R, Terron A, Monnet-Tschudi F, Wilks MF, Witters H, Zurich MG, Bal-Price A.

Toxicol Appl Pharmacol. 2018 Sep 1;354:3-6. doi: 10.1016/j.taap.2018.02.004. Epub 2018 Feb 12.

7.

An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Terron A, Bal-Price A, Paini A, Monnet-Tschudi F, Bennekou SH; EFSA WG EPI1 Members, Leist M, Schildknecht S.

Arch Toxicol. 2018 Jan;92(1):41-82. doi: 10.1007/s00204-017-2133-4. Epub 2017 Dec 5. Review.

8.

International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes.

Bal-Price A, Crofton KM, Leist M, Allen S, Arand M, Buetler T, Delrue N, FitzGerald RE, Hartung T, Heinonen T, Hogberg H, Bennekou SH, Lichtensteiger W, Oggier D, Paparella M, Axelstad M, Piersma A, Rached E, Schilter B, Schmuck G, Stoppini L, Tongiorgi E, Tiramani M, Monnet-Tschudi F, Wilks MF, Ylikomi T, Fritsche E.

Arch Toxicol. 2015 Feb;89(2):269-87. doi: 10.1007/s00204-015-1464-2. Epub 2015 Jan 25.

9.

Putative adverse outcome pathways relevant to neurotoxicity.

Bal-Price A, Crofton KM, Sachana M, Shafer TJ, Behl M, Forsby A, Hargreaves A, Landesmann B, Lein PJ, Louisse J, Monnet-Tschudi F, Paini A, Rolaki A, Schrattenholz A, Suñol C, van Thriel C, Whelan M, Fritsche E.

Crit Rev Toxicol. 2015 Jan;45(1):83-91. doi: 10.3109/10408444.2014.981331. Review.

10.

Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.

Valero-Esquitino V, Lucht K, Namsolleck P, Monnet-Tschudi F, Stubbe T, Lucht F, Liu M, Ebner F, Brandt C, Danyel LA, Villela DC, Paulis L, Thoene-Reineke C, Dahlöf B, Hallberg A, Unger T, Sumners C, Steckelings UM.

Clin Sci (Lond). 2015 Jan;128(2):95-109. doi: 10.1042/CS20130601.

PMID:
25052203
11.

Repeated exposure to Ochratoxin A generates a neuroinflammatory response, characterized by neurodegenerative M1 microglial phenotype.

von Tobel JS, Antinori P, Zurich MG, Rosset R, Aschner M, Glück F, Scherl A, Monnet-Tschudi F.

Neurotoxicology. 2014 Sep;44:61-70. doi: 10.1016/j.neuro.2014.04.005. Epub 2014 May 2.

PMID:
24792326
12.

Immediate and delayed effects of subchronic Paraquat exposure during an early differentiation stage in 3D-rat brain cell cultures.

Sandström von Tobel J, Zoia D, Althaus J, Antinori P, Mermoud J, Pak HS, Scherl A, Monnet-Tschudi F.

Toxicol Lett. 2014 Oct 15;230(2):188-97. doi: 10.1016/j.toxlet.2014.02.001. Epub 2014 Feb 9.

PMID:
24521700
13.

Methods to assess neuroinflammation.

Monnet-Tschudi F, Defaux A, Braissant O, Cagnon L, Zurich MG.

Curr Protoc Toxicol. 2011 Nov;Chapter 12:Unit12.19. doi: 10.1002/0471140856.tx1219s50.

PMID:
22058053
14.

Preparation, maintenance, and use of serum-free aggregating brain cell cultures.

Honegger P, Defaux A, Monnet-Tschudi F, Zurich MG.

Methods Mol Biol. 2011;758:81-97. doi: 10.1007/978-1-61779-170-3_6.

PMID:
21815060
15.

Inflammatory responses in aggregating rat brain cell cultures subjected to different demyelinating conditions.

Defaux A, Zurich MG, Honegger P, Monnet-Tschudi F.

Brain Res. 2010 Sep 24;1353:213-24. doi: 10.1016/j.brainres.2010.07.016. Epub 2010 Jul 16.

PMID:
20638371
16.

Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.

Defaux A, Zurich MG, Braissant O, Honegger P, Monnet-Tschudi F.

J Neuroinflammation. 2009 May 7;6:15. doi: 10.1186/1742-2094-6-15.

17.

Ammonium alters creatine transport and synthesis in a 3D culture of developing brain cells, resulting in secondary cerebral creatine deficiency.

Braissant O, Cagnon L, Monnet-Tschudi F, Speer O, Wallimann T, Honegger P, Henry H.

Eur J Neurosci. 2008 Apr;27(7):1673-85. doi: 10.1111/j.1460-9568.2008.06126.x.

PMID:
18380667
18.

Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-type-specific adverse effects in aggregating brain cell cultures.

Monnet-Tschudi F, Hazekamp A, Perret N, Zurich MG, Mangin P, Giroud C, Honegger P.

Toxicol Appl Pharmacol. 2008 Apr 1;228(1):8-16. Epub 2007 Nov 17.

PMID:
18083204
19.

Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies.

Coecke S, Goldberg AM, Allen S, Buzanska L, Calamandrei G, Crofton K, Hareng L, Hartung T, Knaut H, Honegger P, Jacobs M, Lein P, Li A, Mundy W, Owen D, Schneider S, Silbergeld E, Reum T, Trnovec T, Monnet-Tschudi F, Bal-Price A.

Environ Health Perspect. 2007 Jun;115(6):924-31. Epub 2007 Feb 6.

20.

Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases.

Monnet-Tschudi F, Zurich MG, Boschat C, Corbaz A, Honegger P.

Rev Environ Health. 2006 Apr-Jun;21(2):105-17. Review.

PMID:
16898674

Supplemental Content

Loading ...
Support Center